Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
about
Amino acids as regulators of gene expressionTumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinaseAbnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatmentThe outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Sunitinib in the treatment of metastatic renal cell carcinomaAdvanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendationsRapamycin causes regression of astrocytomas in tuberous sclerosis complexTSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPaseRegulation of TORC1 by Rag GTPases in nutrient responseA circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficitsBrain abnormalities in tuberous sclerosis complex.Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsA phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerA phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Phase II open-label study of sunitinib in patients with advanced breast cancer.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markersFinal results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studyGlobal gene expression analysis of lenses from different mouse strains and in the alpha3Cx46 knockout mouse.Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a reviewDynamic switch of negative feedback regulation in Drosophila Akt-TOR signaling.Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.Investigational agents in development for the treatment of ovarian cancerGene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors.Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation studyA phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.Everolimus - a new approach in the treatment of renal cell carcinomaCongenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six casesERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signalingSunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
P2860
Q24562847-F366A40B-302C-409A-8762-90E41705976EQ24564747-75F0DBB8-5C61-4315-99E0-A0AF201C4EEFQ24651443-118C3115-51BE-446B-8408-90DA2932BCC2Q27318635-32FF4E09-CC67-4982-A686-03FDA4F5B309Q27851744-D3C98DDF-524F-4F91-8B3C-8E5E13078737Q28072057-EBCAE3E1-022E-462D-BDC3-58D1AAFD2A59Q28247449-34E6831A-220C-46F5-A786-DC8737BAB7B4Q28295149-87633BAE-E790-4D19-86E8-3BA800CE268FQ28583834-9BE84EE6-521E-4664-A9A9-83B59D8C660BQ29614478-7ABF0DBF-A956-452D-BC90-61E8775A2431Q30597707-F29CB3BD-D74C-4EF9-9E86-4981223BBABBQ30977127-1EB9A96D-AA37-48DC-BD76-B0BB1851BB37Q31037756-D33D5CB7-FF24-4902-A2F0-BE693FE1E8CEQ33385748-BD765DB7-A611-43A8-8A0D-08DF10D70DEBQ33389519-51EC7CA5-667E-45EE-882F-7B5947294D95Q33393174-59D58AEC-CC26-4AE7-BCBE-ABF23A8F94CFQ33397590-107B61BF-6BE9-4A26-BE91-B1F3F23A70B5Q33401396-C578AC94-CA01-46AB-B998-0C981E4CDB11Q33403848-7303E1CC-C8DA-4EF9-94ED-1B739BC34BBAQ33406542-4FD88847-83B7-4E19-B32F-6F54377BCFCBQ33407676-957370DC-D592-40DB-B731-D4873D1DD0ACQ33409913-9C77378E-A153-4EDC-AE21-E4750494E4F3Q33417933-0F705A5C-3235-43A7-84F3-5A8E7735732CQ33423740-9559F9DF-2538-42F9-9576-29D0EE2CB708Q33559444-34DA8D32-8057-418E-AE5E-06578AC8654DQ33608352-14047ED2-0863-4359-B5D2-EDAD2BF202C2Q33613666-C9F8D47E-8C35-46D8-9331-46ACCD13C9E6Q33617062-ECCD87E0-8576-42CE-B76E-0153B3AF5777Q33619056-50DF1C35-F1D9-4838-BB73-1C55DA20CEE6Q33794403-B21CE326-0124-464B-86AE-3FFDDF2EAEC4Q33920800-6D095273-2653-41E9-A9C4-BEB97439132FQ33926192-BE78EFE1-5C9C-450E-A4FE-0F6383EA21B8Q33996608-18214FB5-9475-488E-AB59-47318223B6B4Q34250125-F3DBA28E-166D-4248-A33E-D66F88898398Q34390606-6A27A86E-05E6-486D-9D1A-3E9C46C43B55Q34417931-FC97692B-05A2-4D9F-8ABE-2BABDFF27C2CQ34468812-DFDA3E6A-4A96-4973-A4DF-69053DCFF4A9Q34893933-2CB18A3F-A31E-4A22-B9E1-042DD41B4F8FQ34979291-E34E57B4-2268-44E9-82CC-FC5FE83C815AQ35114038-9D29F429-BD05-4278-8132-55F703498725
P2860
Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Rhebbing up mTOR: new insights ...... genesis of tuberous sclerosis.
@ast
Rhebbing up mTOR: new insights ...... genesis of tuberous sclerosis.
@en
type
label
Rhebbing up mTOR: new insights ...... genesis of tuberous sclerosis.
@ast
Rhebbing up mTOR: new insights ...... genesis of tuberous sclerosis.
@en
prefLabel
Rhebbing up mTOR: new insights ...... genesis of tuberous sclerosis.
@ast
Rhebbing up mTOR: new insights ...... genesis of tuberous sclerosis.
@en
P356
P1476
Rhebbing up mTOR: new insights ...... genesis of tuberous sclerosis.
@en
P2093
David J Kwiatkowski
P304
P356
10.4161/CBT.2.5.446
P577
2003-09-01T00:00:00Z